Cure My Disease

Don't miss your cure!

 Log in / Sign up

TRX training boosts strength and walking in seniors with sarcopenia

NCT ID NCT07398092

Symptom relief Sponsor: WeiJin Zhang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a 12-week TRX suspension training program could improve physical fitness, walking ability, and blood markers related to inflammation and muscle growth in older men with sarcopenia (age-related muscle loss). 36 men aged 65+ were randomly assigned to either TRX training three times a week or their usual routine. The goal was to see if this type of exercise is a safe and effective way to improve muscle strength, balance, and overall function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male participants aged 65 years or older. * Diagnosis of sarcopenia based on established criteria, including low handgrip strength, reduced skeletal muscle mass index, and slow gait speed. * Ability to walk independently without assistive devices. * Ability to understand the study procedures and provide written informed consent. * Willingness to participate in the 12-week intervention and complete all required assessments. Exclusion Criteria: * Presence of severe cardiovascular disease or other medical conditions that contraindicate moderate-intensity exercise. * Diagnosis of severe depression, dementia, or other neurological or psychiatric disorders that could interfere with participation. * Participation in other structured exercise or training programs during the study period. * History of drug or alcohol abuse. * Any musculoskeletal, neurological, or systemic condition that would prevent safe participation in the exercise intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia

Contacts and locations

Locations

  • Yibin University

    Yibin, Sichuan, 644000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.